Nachrichten zur Sutro Biopharma Inc. Aktie

Sutro Biopharma (NASDAQ:STRO) shareholders have endured a 80% loss from investing in the stock three years ago

As every investor would know, not every swing hits the sweet spot. But you have a problem if you face…

Sutro Biopharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Sept. 20, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:…

Sutro Biopharma to Host Research Forum Highlighting Next-Generation ADC Innovation and Near-term Pipeline, on October 10, 2024

SOUTH SAN FRANCISCO, Calif., Sept. 11, 2024 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:…

Sutro Biopharma (STRO) Rises 9% in the Past Week: Heres Why

Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to…

Coping with a Wild Ride: Investing in Sutro Biopharma (NASDAQ:STRO)

Short-term volatility is the hallmark of clinical-stage biopharma investing, and Sutro Biopharma (NASDAQ:STRO) is a fine example of that, recently…

Coping with a Wild Ride: Investing in Sutro Biopharma (NASDAQ:STRO)

Short-term volatility is the hallmark of clinical-stage biopharma investing, and Sutro Biopharma (NASDAQ:STRO) is a fine example of that, recently…

Sutro Biopharma, Inc. (STRO) Q4 Earnings and Revenues Surpass Estimates

Sutro Biopharma (STRO) delivered earnings and revenue surprises of 151.22% and 834.90%, respectively, for the quarter ended December 2023. Do…

Sutro Biopharma, Inc. (STRO) Surges 9.5%: Is This an Indication of Further Gains?

Sutro Biopharma, Inc. (STRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in…

Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates

-- Vaxcyte Obtains Exclusive Rights to Independently Develop and Manufacture Cell-Free Extract, a Key Component of the Company’s Pneumococcal Conjugate…

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sutro Biopharma, Inc. (NASDAQ: STRO) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Sutro Biopharma,…

Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:…

Sutro Biopharma: Luvelta Data For Endometrial Cancer Treatment Approaching

…

Sutro Biopharma GAAP EPS of -$0.64 beats by $0.07, revenue of $10.4M misses by $3.2M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sutro Biopharma, Inc. (STRO) Reports Q2 Loss, Lags Revenue Estimates

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 12.33% and 0.33%, respectively, for the quarter ended June 2023.…

Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones

- Enrollment is underway for REFRaME-O1, the Phase 2/3 pivotal study of luveltamab tazevibulin, or luvelta, for patients with platinum-resistant…

Form 8-K SUTRO BIOPHARMA, INC. For: Aug 10

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

All You Need to Know About Sutro Biopharma, Inc. (STRO) Rating Upgrade to Buy

Sutro Biopharma, Inc. (STRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the companys earnings…

Form 8-K SUTRO BIOPHARMA, INC. For: Jun 08

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K SUTRO BIOPHARMA, INC. For: May 15

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sutro Biopharma to Present at the JMP Securities Life Sciences Conference

SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:…

Sutro Biopharma, Inc. (STRO) Soars 11.3%: Is Further Upside Left in the Stock?

Sutro Biopharma, Inc. (STRO) saw its shares surge in the last session with trading volume being higher than average. The…

Sutro Biopharma, Inc. (STRO) May Report Negative Earnings: Know the Trend Ahead of Q1 Release

Sutro Biopharma, Inc. (STRO) doesnt possess the right combination of the two key ingredients for a likely earnings beat in…

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

SOUTH SAN FRANCISCO, Calif., April 27, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:…

Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023

ORLANDO, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a…

Form 8-K SUTRO BIOPHARMA, INC. For: Apr 10

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Where Sutro Biopharma Stands With Analysts

Latest Ratings for STRO DateFirmActionFromTo Nov 2021BerenbergInitiates Coverage OnBuy Jun 2021HC Wainwright & Co.Initiates Coverage OnBuy Dec 2020StifelInitiates Coverage…

Sutro Biopharma GAAP EPS of -$2.35 beats by $0.16, revenue of $67.8M misses by $0.57M

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Misses Revenue Estimates

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of 4.69% and 24.95%, respectively, for the quarter ended December 2022.…

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

- Sutro plans to initiate a Phase 2/3 registration-directed study of luvelta for patients with platinum resistant ovarian cancer in…

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:…

Sutro Biopharma appoints Borgman as Chief Medical Officer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:…

Form 8-K SUTRO BIOPHARMA, INC. For: Feb 24

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:…

Sutro Biopharma Posts Updated Data From Ovarian Cancer Candidate

Form 8-K SUTRO BIOPHARMA, INC. For: Jan 09

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 04, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:…

Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer

- Conference call and webcast to be held on Monday, January 9, 2023 at 1:30 pm PT, or 4:30 pm…

Vaxcyte acquires option from Sutro Biopharma to expand rights to make cell-free extract

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract

- New Agreement Provides Vaxcyte Access to Expanded Rights to Develop and Manufacture Cell-Free Extract, a Key Component of Vaxcytes…

Form 8-K SUTRO BIOPHARMA, INC. For: Dec 19

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022

- A total of 17 pediatric patients were treated with STRO-002 on a compassionate use basis; eight patients achieved complete…

dpa-AFX ProFeed